Merck Can't Arbitrate Antitrust Suit Over Vaccine Bundles

By Lauren Berg · January 23, 2019, 9:22 PM EST

Merck Sharp & Dohme Corp. cannot force each individual in a proposed class action to arbitrate claims that its pediatric vaccine bundles with alleged artificially inflated price tags are anti-competitive, a...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum and/or Opinion

Case Information

Case Title

IN RE ROTAVIRUS VACCINES ANTITRUST LITIGATION

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

April 25, 2018

Recent Articles By Lauren

November 20, 2024
Musk, Ramaswamy Say High Court Rulings OK Federal Cuts
November 15, 2024
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping
November 12, 2024
J&J Says HHS Is Thwarting Transparency Of Drug Discounts
October 30, 2024
FDA Didn't Flub Approval In Orphan Drug Case, DC Court Says
October 18, 2024
Oklahoma Brings Title X Funding Cut Fight To Justices
October 11, 2024
Feds Target Ill. Hospital CEO As $19M Theft Probe Widens
October 11, 2024
Quinn Emanuel Gets Trimmed $92M Fee In ACA Cases
September 30, 2024
Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
September 30, 2024
Bristol-Myers Beats Celgene Investors' Drug Delay Suit
September 27, 2024
9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule